Clinical trialPhase 1Recruiting

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

NCT06500052 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Ongoing
Phase: Phase 1
Status: Recruiting
Study type: Interventional
Start: 24 July 2024
Expected end: August 2026
Enrollment: 20 participants
Sites: 1
Primary outcomes: Phase Ia: Dose limiting toxicity (DLT); Phase Ia: Maximum tolerated dose (MTD); Phase Ib: Recommended Phase II Dose (RP2D)
Sponsor: Industry
Results posted: No
Last update: 18 September 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors.